Humankind Investments LLC Sells 2,187 Shares of Gilead Sciences, Inc. $GILD

Key Points

• Humankind Investments LLC has reduced its stake in Gilead Sciences by 17.8%, selling 2,187 shares and now holding a total of 10,070 shares valued at approximately $1,128,000.
• Analysts are optimistic about Gilead Sciences, with several firms raising their price targets; Morgan Stanley increased its target from $130 to $135, while Needham upgraded the stock to a buy rating with a target of $133.
• Gilead Sciences has announced a quarterly dividend of $0.79 per share, with an annualized yield of 2.7%, payable on September 29 to investors of record on September 15.

Humankind Investments LLC decreased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 17.8% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 10,070 shares of the biopharmaceutical company's stock after selling 2,187 shares during the period. Humankind Investments LLC's holdings in Gilead Sciences were worth $1,128,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Smallwood Wealth Investment Management LLC bought a new stake in shares of Gilead Sciences during the 1st quarter worth about $25,000. Goodman Advisory Group LLC bought a new stake in shares of Gilead Sciences during the 1st quarter worth about $29,000. Colonial Trust Advisors boosted its holdings in shares of Gilead Sciences by 304.3% during the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 213 shares during the period. Core Alternative Capital boosted its holdings in shares of Gilead Sciences by 370.8% during the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 241 shares during the period. Finally, IMA Advisory Services Inc. bought a new stake in Gilead Sciences in the 1st quarter valued at about $39,000. Institutional investors own 83.67% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. Morgan Stanley boosted their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Daiwa Capital Markets raised shares of Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price objective for the company in a report on Tuesday. Oppenheimer cut their price objective on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, April 25th. Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price objective for the company in a report on Friday, July 25th. Finally, Truist Financial raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and boosted their price objective for the company from $108.00 to $127.00 in a report on Friday, August 8th. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat, Gilead Sciences currently has an average rating of "Moderate Buy" and an average price target of $115.39.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction that occurred on Tuesday, July 15th. The shares were sold at an average price of $111.03, for a total transaction of $277,575.00. Following the completion of the transaction, the chief financial officer directly owned 162,610 shares in the company, valued at $18,054,588.30. This represents a 1.51% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the company's stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $109.74, for a total transaction of $548,700.00. Following the transaction, the director owned 8,920 shares of the company's stock, valued at approximately $978,880.80. This represents a 35.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 110,000 shares of company stock valued at $12,349,790 in the last quarter. 0.27% of the stock is owned by company insiders.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $117.98 on Wednesday. The firm has a 50 day moving average of $112.14 and a 200-day moving average of $108.71. The stock has a market capitalization of $146.39 billion, a PE ratio of 23.50, a PEG ratio of 0.72 and a beta of 0.33. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 12 month low of $74.34 and a 12 month high of $121.83.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.96 by $0.05. The company had revenue of $7.08 billion during the quarter, compared to analysts' expectations of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business's revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period in the previous year, the company earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Monday, September 15th. Gilead Sciences's dividend payout ratio is currently 62.95%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.